Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|March 5, 2018
NonDriver Metastatic Lung Large Cell Carcinoma
NonDriver Metastatic Lung Large Cell Carcinoma
Advertisement
- A 70-year old woman presented with persistent cough and congestion lasting more than 6 months
- She is a non-smoker; drinks alcohol 1-2 times/week
- PMH: Crohn’s disease managed on infliximab; hypothyroidism, moderately well-managed on levothyroxine; osteoarthritis managed PRN on naproxen
- Her physical exam and cardiac workup were normal
- CBC; WNL
- PS by ECOG assessment is 2
- Chest X-Ray showed mass in the upper right lung
- CT of the chest, abdomen, and pelvis showed a solid 6 X 8 cm. Right-sided pleural mass abutting the apical aspect of the chest wall and 2 small hepatic nodules measuring 1.5 cm and 2 cm.
- Bronchoscopy and biopsy of the lung mass was performed; pathology was consistent with large cell carcinoma
- Genetic testing was negative for known driver mutations
- PD-L1 testing by IHC showed expression in 2% of cells
- Brain MRI showed no evidence of CNS disease
- Diagnosis; stage IV NSCLC
- The patient was started on therapy with carboplatin and paclitaxel and bevacizumab
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5